Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Regulatory symbols : Azn save search
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
AZNCF | $135.305 -4.19% 1.1K
|
Health Technology
|
| O: 1.47%
H: 1.16%
C: -1.27%
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: 3.34%
H: 0.27%
C: -0.62%
children approved treatment for
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Published: 2024-04-02 (Crawled : 08:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: -1.18%
H: 0.34%
C: -0.22%
breast her2 license cancer application negative
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Published: 2022-08-12 (Crawled : 08:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: 0.09%
H: 3.83%
C: 2.98%
enhertu lung approved therapy cancer her2- her2
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast Cancer
Published: 2022-07-25 (Crawled : 11:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: 1.43%
H: 0.39%
C: -0.04%
enhertu granted review cancer her2- her2 metastatic breast cancer
ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: -1.35%
H: 0.4%
C: -1.2%
enhertu approved positive cancer breast cancer her2- her2 metastatic breast cancer
ENHERTU® Granted Priority Review in the U.S. for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Published: 2022-04-19 (Crawled : 11:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: -0.44%
H: 0.66%
C: -0.42%
enhertu granted review cancer her2- her2
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Published: 2022-01-17 (Crawled : 09:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
| Email alert
Add to watchlist
enhertu granted positive cancer breast cancer her2- her2 metastatic breast cancer
Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca's anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)
Published: 2021-08-02 (Crawled : 12:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: -0.7%
H: 0.86%
C: 0.58%
fda fda approval research approval lupus
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.